Opaganib manufacturing is to be expanded with two Canadian and European firms.
RedHill Biopharma, an Israeli bio-medical firm, has announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of Opaganib, a new Covid-19 treatment currently being developed.
The collaborations are for the large scale manufacture of Opaganib should it be approved for use.
We are all praying for whatever treatment or vaccine that can be produced which will at least stop the spread or worst effects of Covid-19. This would at least allow for the end of these awful closures.
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, potentially minimizing the likelihood of viral resistance.
In studies Opaganib demonstrated potent anti-SARS-CoV-2 activity, achieving complete blockage of viral replication in an in vitro model of human lung tissue.
Today marks the beginning of @IAmBiotech’s #BIFDigital 2020! Click here to listen to #RDHL’s Chief Business Officer, Guy Goldberg’s presentation: https://t.co/7Rl2u0w5IP $RDHL pic.twitter.com/3ZVWYCpn0T
— RedHill Biopharma (@RedHillBio) October 13, 2020
“In light of the rapid progress of our Phase 2/3 COVID-19 development program with opaganib, we are expanding manufacturing capabilities and capacity for opaganib with trusted and high-quality partners, to meet likely demand ahead of potential global emergency use applications,” said Reza Fathi, PhD., RedHill’s Senior VP, R&D.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults2, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults3, and Aemcolo® for the treatment of travelers’ diarrhea in adults4.
RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi) RHB-106, an encapsulated bowel preparation.